Piper Sandler Initiates Coverage On Enfusion with Overweight Rating, Announces Price Target of $26
Piper Sandler analyst Christopher Donat initiates coverage on Enfusion (NYSE:ENFN) with a Overweight rating and announces Price Target of $26.